Pfizer/BioNTech, Moderna Vaccines Take Baby Steps Into Booster Shots

Moderna may benefit from data indicating strong efficacy against the Delta strain, though an analyst pointed out that they come with some important caveats.

Adolescent covid vaccination US
The FDA expanded the EUAs for Pfizer/BioNTech and Moderna's COVID-19 vaccines to include third shots for severely immunocompromised individuals • Source: Shutterstock

While the commercial position of Pfizer Inc./BioNTech SE’s and Moderna, Inc.’s COVID-19 vaccines would strengthen if it is recommended that people who received the initial two-dose vaccination series of BNT162b2 or mRNA-1273 get boosters, the US Food and Drug Administration’s expansion of the vaccines’ emergency use authorizations to include third shots for certain vulnerable people accounts for only a very small number of patients. But as variants of concern continue spreading, Moderna may have an upper hand, with data showing strong efficacy against the Delta strain, though those results come with certain caveats.

The FDA said late on 12 August that it amended the EUAs for the two vaccines to allow for additional...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain

 

Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.

Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy

 

The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.

AstraZeneca Moves To Join Invyvid In COVID-19 Prevention

 

The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.    

Stock Watch: Thoroughly Moderna Missteps

 
• By 

When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

Test

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.